Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 02, 2025
Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.
Journal: Annals of surgical oncology
Published: May 29, 2024
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 19, 2023
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Journal: Journal of the National Cancer Institute
Published: October 24, 2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Journal: Clinical nuclear medicine
Published: May 04, 2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Journal: American journal of clinical oncology
Published: May 04, 2022
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: July 12, 2021
High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.
Journal: Future oncology (London, England)
Published: January 28, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 10, 2020
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 10, 2020
Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 11, 2020
Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Journal: Surgical oncology clinics of North America
Published: March 11, 2020
Last Updated: 09/26/2026